Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine ; volume:36 ; number:12 ; day:23 ; month:10 ; year:2019 ; pages:3321-3339 ; date:12.2019
Advances in therapy ; 36, Heft 12 (23.10.2019), 3321-3339, 12.2019
- Creator
-
Handelsman, Yehuda
Muskiet, Marcel H. A.
Meneilly, Graydon S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-019-01126-x
- URN
-
urn:nbn:de:101:1-2020050321510509993720
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Handelsman, Yehuda
- Muskiet, Marcel H. A.
- Meneilly, Graydon S.
- SpringerLink (Online service)
Other Objects (12)
Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
Switching the basal insulin to insulin glargine 300 u/ml in people with type 2 diabetes under basal insulin supported oral therapy – observational trial on effectiveness and safety
Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study
Se‐Glargine: Chemical Synthesis of a Basal Insulin Analogue Stabilized by an Internal Diselenide Bridge
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence
Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
Switching the basal insulin to insulin glargine 300 u/ml in people with type 2 diabetes under basal insulin supported oral therapy – observational trial on effectiveness and safety
Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study
Se‐Glargine: Chemical Synthesis of a Basal Insulin Analogue Stabilized by an Internal Diselenide Bridge
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence
Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
Switching the basal insulin to insulin glargine 300 u/ml in people with type 2 diabetes under basal insulin supported oral therapy – observational trial on effectiveness and safety
Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study
Se‐Glargine: Chemical Synthesis of a Basal Insulin Analogue Stabilized by an Internal Diselenide Bridge
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence
Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats